Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Perinatal Medicine

Official Journal of the World Association of Perinatal Medicine

Editor-in-Chief: Dudenhausen, MD, FRCOG, Joachim W.

Editorial Board: / Bancalari, Eduardo / Greenough, Anne / Genc, Mehmet R. / Chervenak, Frank A. / Chappelle, Joseph / Bergmann, Renate L. / Bernardes, J.F. / Bevilacqua, G. / Blickstein, Isaac / Cabero Roura, Luis / Carbonell-Estrany, Xavier / Carrera, Jose M. / D`Addario, Vincenzo / D'Alton, MD, Mary E. / Dimitrou, G. / Grunebaum, Amos / Hentschel, Roland / Köpcke, W. / Kawabata, Ichiro / Keirse, Marc J.N.C. / Kurjak M.D., Asim / Lee, Ben H. / Levene, Malcolm / Lockwood, Charles J. / Marsal, Karel / Makatsariya, Alexander / Nishida, Hiroshi / Papp, Zoltán / Pejaver, Ranjan Kumar / Pooh, Ritsuko K. / Reiss, Irwin / Romero, Roberto / Saugstad, Ola D. / Schenker, Joseph G. / Sen, Cihat / Seri, Istvan / Vetter, Klaus / Winn, Hung N. / Young, Bruce K. / Zimmermann, Roland

9 Issues per year


IMPACT FACTOR 2016: 1.577
5-year IMPACT FACTOR: 1.705

CiteScore 2016: 1.49

SCImago Journal Rank (SJR) 2016: 0.602
Source Normalized Impact per Paper (SNIP) 2016: 0.832

Online
ISSN
1619-3997
See all formats and pricing
More options …
Volume 44, Issue 5

Issues

Oral propranolol in early stages of retinopathy of prematurity

Aldo Bancalari / Ricardo Schade / Tomás Muñoz / Carolina Lazcano / Rodrigo Parada / Rubén Peña
Published Online: 2016-02-04 | DOI: https://doi.org/10.1515/jpm-2015-0357

Abstract

Objective: To assess the effect of oral propranolol on the progression of early stages of retinopathy of prematurity (ROP) in very low birth weight (VLBW) infants.

Methods: We analyzed VLBW infants with ROP (stages 2–3, zones II-III). Newborns received oral propranolol (0.5 mg/kg/dose q8h), and were monitored throughout the treatment period for possible side effects. Propranolol was administered until regression of ROP. A historic control group of patients with equivalent ROP was used. We compared characteristics of both groups and the progression of retinopathy.

Results: Forty-seven newborns were included, 20 in the propranolol group and 27 in the control group. There were no significant differences in gestational age, birthweight or gender. The mean duration of treatment with propranolol was 58.2±17.6 days. Most patients started treatment with stage 2 disease (65.0%), and had zone III involvement (55.0%). In the treated group, 90.0% (18/20) of patients did not require intervention with laser or bevacizumab, compared to 51.8% in the control group (P<0.005). No cases of bradycardia, hypotension or hypoglycemia were observed.

Conclusions: Oral propranolol in early stages of ROP could prevent disease progression and reduce the need for invasive rescue therapy with laser or bevacizumab. No significant side effects were reported.

Keywords: Beta-adrenoreceptor; beta-blockers; prematurity; propranolol; retinal neovascularization; ROP; very low birthweight

References

  • [1]

    Raghuveer TS, Bloom BT. A paradigm shift in the prevention of retinopathy of prematurity. Neonatology 2011;100:116–29.Web of ScienceGoogle Scholar

  • [2]

    Bancalari A, González R, Vásquez C, Pradenas I. Retinopathy of prematurity: incidence and associated factors. Rev Chil Pediatr. 2000;71:114–21.Google Scholar

  • [3]

    Cavallaro G, Filippi L, Bagnoli P, La Marca G, Cristofori G, Raffaeli G, et al. The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge. Acta Ophthalmol. 2014;92:2–20.Google Scholar

  • [4]

    Ristori C, Filippi L, Dal Monte M, Martini D, Cammalleri M, Fortunato P, et al. Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. Invest Ophthalmol Vis Sci. 2011;52:155–70.Web of ScienceGoogle Scholar

  • [5]

    Lavine JA, Sang Y, Wang S, Ip MS, Sheibani N. Attenuation of choroidal neovascularization by β(2)-adrenoreceptor antagonism. JAMA Ophthalmol. 2013;13:376–82.Web of ScienceGoogle Scholar

  • [6]

    Starkey E, Shahidullah H. Propranolol for infantile haemangiomas: a review. Arch Dis Child. 2011;96:890–3.Web of ScienceGoogle Scholar

  • [7]

    Tang J, Li Z, Lu L, Cho CH. β-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy. Semin Cancer Biol. 2013;23:533–42.Web of ScienceGoogle Scholar

  • [8]

    Ciccarelli M, Sorriento D, Cipolletta E, Santulli G, Fusco A, Zhou RH, et al. Impaired neoangiogenesis in β2-adrenoceptor gene-deficient mice: restoration by intravascular human β2-adrenoceptor gene transfer and role of NFkB and CREB transcription factors. Br J Pharmacol. 2011;162:712–21.Web of ScienceGoogle Scholar

  • [9]

    Dal Monte M, Cammalleri M, Mattei E, Filippi L, Bagnoli P. Protective effects of β1/2 adrenergic receptor deletion in a model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2014;56:59–73.Google Scholar

  • [10]

    Greenhouse JM, Szewczyk T. Skin hemangioma and retrolental fibroplasia. AMA Arch Derm. 1956;73:568–71.Google Scholar

  • [11]

    Praveen V, Vidavalur R, Rosenkrantz T, Hussain N. Infantile hemangiomas and retinopathy of prematurity: posible association. Pediatrics 2009;123:e484–9.Web of ScienceGoogle Scholar

  • [12]

    Bancalari A, Schade R, Peña R, Pavez N. Intravitreal bevacizumab as single drug therapy for retinopathy of prematurity in 12 patients. Arch Argent Pediatr. 2014;112:160–3.Google Scholar

  • [13]

    Good WV. Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial. Arch Ophthalmol. 2003;121:1684–94.Google Scholar

  • [14]

    Casini G, Dal Monte M, Fornaciari I, Filippi L, Bagnoli P. The β-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases. Prog Retin Eye Res. 2014;42C:103–29.Google Scholar

  • [15]

    Bührer C, Bassler D. Oral propranolol: a new treatment for infants with retinopathy of prematurity? Neonatology 2015;108:49–52.Web of ScienceGoogle Scholar

  • [16]

    Martini D, Monte MD, Ristori C, Cupisti E, Mei S, Fiorini P, et al. Antiangiogenic effects of β2-adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy. J Neurochem. 2011;119:1317–29.Google Scholar

  • [17]

    Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372:735–46.Google Scholar

  • [18]

    Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol. 2009;26:610–4.Google Scholar

  • [19]

    Lamy S, Lachambre MP, Lord-Dufour S, Béliveau R. Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vascul Pharmacol. 2010;53:200–8.Google Scholar

  • [20]

    Filippi L, Cavallaro G, Bagnoli P, Dal Monte M, Fiorini P, Donzelli G, et al. Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. J Pediatr. 2013;163:1570–7.Google Scholar

  • [21]

    Makhoul IR, Peleg O, Miller B, Bar-Oz B, Kochavi O, Mechoulam H, et al. Oral propranolol versus placebo for retinopathy of prematurity: a pilot, randomised, double-blind prospective study. Arch Dis Child. 2013;98:565–7.Web of ScienceGoogle Scholar

  • [22]

    International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. 2005;123:991–9.Google Scholar

  • [23]

    Nuntnarumit P, Yang W, Bada-Ellzey HS. Blood pressure measurements in the newborn. Clin Perinatol. 1999;26:981–96.Google Scholar

  • [24]

    Austeng D, Källen KB, Hellström A, Tornqvist K, Holmström GE. Natural history of retinopathy of prematurity in infants born before 27 weeks gestation in Sweden. Arch Ophthalmol. 2010;128:1289–94.Google Scholar

  • [25]

    Chen YH, Lien RI, Tsai S, Chang CJ, Lai CC, Chao AN, et al. Natural history of retinopathy of prematurity: two-year outcomes of a prospective study. Retina 2015;35:141–8.Google Scholar

  • [26]

    Padrini L, Isacchi B, Bilia AR, Pini A, Lanzi C, Masini E, et al. Pharmacokinetics and local safety profile of propranolol eye drops in rabbits. Pediatr Res. 2014;76:378–85.Google Scholar

About the article

Corresponding author: Dr. Aldo Bancalari, San Martin 1436, Concepción, Chile 4070038, Tel.: 56-41-2722698, E-mail: ; and Neonatology Department, Guillermo Grant Benavente Hospital, Concepción, Biobio, Chile


Received: 2015-10-22

Accepted: 2015-12-22

Published Online: 2016-02-04

Published in Print: 2016-07-01


Funding: No additional funding, equipment or supplies were necessary.

The authors stated that there are no conflicts of interest regarding the publication of this article.


Citation Information: Journal of Perinatal Medicine, Volume 44, Issue 5, Pages 499–503, ISSN (Online) 1619-3997, ISSN (Print) 0300-5577, DOI: https://doi.org/10.1515/jpm-2015-0357.

Export Citation

©2016 by De Gruyter. Copyright Clearance Center

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Tatjana Šarenac-Vulović, Sunčica Srećković, Nenad Petrović, Mirjana Janićijević-Petrović, Svetlana Jovanović, and Dušan Todorović
Medicinski casopis, 2017, Volume 51, Number 4, Page 131
[2]
Siree Kaempfen, Roland P Neumann, Kerstin Jost, and Sven M Schulzke
Cochrane Database of Systematic Reviews, 2018
[3]
Maurizio Cammalleri, Filippo Locri, Elisabetta Catalani, Luca Filippi, Davide Cervia, Massimo Dal Monte, and Paola Bagnoli
Frontiers in Cellular Neuroscience, 2017, Volume 11
[4]
Senthil Selvam, Tejas Kumar, and Marcus Fruttiger
Progress in Retinal and Eye Research, 2017
[5]
Luca Filippi, Giacomo Cavallaro, Elettra Berti, Letizia Padrini, Gabriella Araimo, Giulia Regiroli, Valentina Bozzetti, Chiara De Angelis, Paolo Tagliabue, Barbara Tomasini, Giuseppe Buonocore, Massimo Agosti, Angela Bossi, Gaetano Chirico, Salvatore Aversa, Roberta Pasqualetti, Pina Fortunato, Silvia Osnaghi, Barbara Cavallotti, Maurizio Vanni, Giulia Borsari, Simone Donati, Giuseppe Nascimbeni, Giancarlo la Marca, Giulia Forni, Silvano Milani, Ivan Cortinovis, Paola Bagnoli, Massimo Dal Monte, Anna Maria Calvani, Alessandra Pugi, Eduardo Villamor, Gianpaolo Donzelli, and Fabio Mosca
BMC Pediatrics, 2017, Volume 17, Number 1

Comments (0)

Please log in or register to comment.
Log in